Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies

CD20 has proven to be an excellent target for the treatment of B-cell lymphoma, first for the chimeric monoclonal antibody rituximab (Rituxan™), and more recently for the radiolabelled antibodies Y-90 ibritumomab tiuxetan (Zevalin™) and I-131 tositumomab (Bexxar™). Radiation therapy effects are due to beta emissions with path lengths of 1–5 mm; gamma radiation emitted by I-131 is the only radiation safety issue for either product. Dose-limiting toxicity for both radiolabelled antibodies is reversible bone marrow suppression. They produce response rates of 70%–90% in low-grade and follicular lymphoma and 40%–50% in transformed low-grade or intermediate-grade lymphomas. Both products produce higher response rates than related unlabelled antibodies, and both are highly active in patients who are relatively resistant to rituximab-based therapy. Median duration of response to a single course of treatment is about 1 year with complete remission rates that last 2 years or longer in about 25% of patients. Clinical trials suggest that anti- CD20 radioimmunotherapy is superior to total body irradiation in patients undergoing stem cell supported therapy for B-cell lymphoma, and that it is a safe and efficacious modality when used as consolidation therapy following chemotherapy. Among cytotoxic treatment options, current evidence suggests that one course of anti-CD20 radioimmunotherapy is as efficacious as six to eight cycles of combination chemotherapy. A major question that persists is how effective these agents are in the setting of rituximab- refractory lymphoma. These products have been underutilised because of the complexity of treatment coordination and concerns regarding reimbursement

Genetic insights into resting heart rate and its role in cardiovascular disease.

Resting heart rate is associated with cardiovascular diseases and mortality in observational and Mendelian randomization studies. The aims of this study are to extend the number of resting heart rate associated genetic variants and to obtain further insights in resting heart rate biology and its clinical consequences. A genome-wide meta-analysis of 100 studies in up to 835,465 individuals reveals 493 independent genetic variants in 352 loci, including 68 genetic variants outside previously identified resting heart rate associated loci. We prioritize 670 genes and in silico annotations point to their enrichment in cardiomyocytes and provide insights in their ECG signature. Two-sample Mendelian randomization analyses indicate that higher genetically predicted resting heart rate increases risk of dilated cardiomyopathy, but decreases risk of developing atrial fibrillation, ischemic stroke, and cardio-embolic stroke. We do not find evidence for a linear or non-linear genetic association between resting heart rate and all-cause mortality in contrast to our previous Mendelian randomization study. Systematic alteration of key differences between the current and previous Mendelian randomization study indicates that the most likely cause of the discrepancy between these studies arises from false positive findings in previous one-sample MR analyses caused by weak-instrument bias at lower P-value thresholds. The results extend our understanding of resting heart rate biology and give additional insights in its role in cardiovascular disease development

ELECTRONIC PROPERTIES OF MOLYBDENUM-IRON-SULFUR-CLUSTERS : APPROACHES TO THE MOLYBDENUM SITE IN NITROGENASE

No abstract availabl

Tropical forests and global change: biogeochemical responses and opportunities for cross-site comparisons, an organized INSPIRE session at the 108th Annual Meeting, Ecological Society of America, Portland, Oregon, USA, August 2023

Tropical forests play a critical role in the global carbon (C) cycle. These ecosystems maintain the highest rates of net primary production (NPP) on Earth (Hengl et al., 2017), contain c. 30% of terrestrial C stocks (Jobbagy & Jackson, 2000), and have some of the largest stores of fine-root biomass globally (Jackson et al., 1996), as well as higher fine-root production and turnover rates compared with other biomes (Cusack et al., 2021). Tropical forest responses to projected warming, altered rainfall regimes, and elevated C dioxide (CO2) concentrations (IPCC, 2021) are likely to be different from other ecosystems because of their unique characteristics (Box 1), making targeted research and model development important for understanding tropical forest–climate feedbacks. There is now a critical mass of long-term global change field experiments and modeling efforts in tropical forests, yet thus far there has been little synthesis, cross-site comparison, or multi-site standardized experimentation among tropical forests to help us understand how these biomes are changing. An organized INSPIRE session at the 108th Annual Meeting of the Ecological Society of America set out to tackle just this. Speakers covered large-scale tropical forest field experiments and modeling efforts, with an emphasis on changes in ecosystem biogeochemistry under warming, drying, elevated atmospheric CO2, and changing nutrient status. In this meeting report, we provide an overview of the large-scale global change experiments presented and highlight the main objectives and opportunities for tropical forest research that emerged, including cross-site comparisons and integration with ecosystem-scale models (Fig. 1)